Clinical DevelopmentXenetic's entry into clinical development for advanced pancreatic cancer with DNase I marks an important step in evaluating its potential in oncology.
CollaborationsThe collaboration with PeriNess Ltd. enhances the potential for regulatory approval and operational execution of DNase I studies in Israeli medical centers.
Preclinical FindingsPreclinical studies indicate that DNase I, when combined with CAR-T therapy, significantly suppresses metastatic tumor burden and prolongs survival in murine models.